Cardiotoxicity & Trastuzumab

Trastuzumab is associated with cardiotoxicity, which can manifest as an asymptomatic decrease in left ventricular ejection fraction (LVEF) and, less frequently, as clinical heart failure (HF)
Koulaouzidis et al. 2021 Curr Problems in Cancer 45: 100723

A total of 35 studies were included in the analysis. The following risk factors were significantly associated with the development of cardiotoxicity:

• Age: OR: 0.7; 95% CI: 0.318-1.09; P = 0.0004


• Hypertension: OR: 0.69; 95% CI: 0.26-1.12; P = 0.001


• Smoking: OR: 0.35; 95% CI: 0.01-0.69; P = 0.038


• Diabetes Mellitus: OR: 0.44; 95% CI: 0.24-0.68; P = 0.0001


• Family History of CAD: OR: 5.51; 95% CI: 1.76-17.25; P < 0.00001


• Known History of CAD: OR: 3.72; 95% CI: 2.11-6.57; P = 0.0005
  *CAD = [Atherosclerosis…